Qiagen, Incyte announce collaboration to develop companion diagnostics
QIAGEN (QGEN) and Incyte (INCY) announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms, a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin, which is being developed in myelofibrosis and essential thrombocythemia. Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Natural Gas Services Group, Inc. Announces Transition of Stephen C. Taylor to Chairman Emeritus and Appointment of Donald J. Tringali as Chairman of the Board
Midland, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Natural Gas Services Group, Inc. (NYSE: NGS), a leading provider of natural gas compression equipment, technology, and services to the energy industry, today announced that Stephen C. Taylor has transitioned from Chairman of the Board to the role of Chairman Emeritus, effective immediately. Concurrently, the Company's Board of Directors has appointed Donald J. Tringali as Chairman. Mr. Taylor continues his role as a director on the Company's Board. This transition marks a significant milestone for Natural Gas Services Group. Mr. Taylor has played an integral role in shaping the Company's direction, growth, and culture over the past two decades. Since his appointment as Chief Executive Officer in 2005, he has overseen the transformation of NGS into a national compression platform, expanding its fleet, footprint, and capabilities across major U.S. oil and gas basins, in addition to leading the Company into the large horsepower market. In the fiscal year prior to his appointment as CEO, NGS reported $7.8 million in EBITDA. By the time of his retirement as CEO in 2024, EBITDA had increased nearly sixfold to $45.8 million, reflecting a significant expansion of NGS's customer base, equipment portfolio, and field service infrastructure. This performance was achieved while maintaining a strong balance sheet and an enduring focus on shareholder value. Following his service as CEO, Mr. Taylor remained Chairman of the Board, where he continued to provide sound guidance and institutional knowledge during a period of transition. His dedication to the Company, its people, and its mission has been unwavering, and he leaves the Chairman role with NGS well-positioned for continued success as evidenced by NGS's industry leading organic growth. 'On behalf of the entire organization and the Board, I want to express our deepest gratitude to Steve for his extraordinary leadership and service,' said Justin Jacobs, Chief Executive Officer of NGS. 'The strength of our Company today is a direct result of his vision and discipline over many years. During my own transition into the CEO role, Steve provided invaluable support that helped ensure continuity and confidence among all stakeholders. He is a trusted advisor and a model of steady, principled leadership. We are fortunate that he will continue to serve as a director and remain one of our largest shareholders.' Mr. Taylor reflected, 'It has been a great privilege to serve Natural Gas Services Group over the past 20 years. I am proud of the progress we have made—from a small, regional provider to a trusted leader in natural gas compression. That progress is a credit to the people of NGS, whose integrity, technical excellence, and commitment to service have always defined our success. I want to thank our customers, employees, partners, and shareholders for their support. With a strong executive team, a clear strategy, and a culture rooted in operational excellence, I believe NGS is poised for continued great achievement. I look forward to continue supporting the Company in this next chapter.' Mr. Tringali, who has served on the NGS Board as an independent director, assumes the role of Chairman with a strong understanding of the Company's business and strategic priorities. He brings significant experience in corporate governance and has been a valuable contributor to the Board's oversight and direction. 'It is an honor to step into the role of Chairman,' said Mr. Tringali. 'Steve's leadership has been foundational to the success and reputation of Natural Gas Services Group. He has overseen an era of meaningful expansion and has fostered a culture of professionalism and long-term thinking that will endure. I look forward to working closely with Justin, the Board, and the management team as we continue to advance the Company's strategy and deliver value to shareholders. Steve's continued involvement on the Board will be an important asset as we move forward.' About Natural Gas Services Group, Gas Services Group is a leading provider of natural gas compression equipment, technology and services to the energy industry. The Company designs, rents, sells and maintains natural gas compressors for oil and natural gas production and plant facilities, primarily using equipment from third-party fabricators and OEM suppliers along with limited in-house assembly. The Company is headquartered in Midland, Texas, with a fabrication facility located in Tulsa, Oklahoma, and service facilities located in major oil and natural gas producing basins in the U.S. Additional information can be found at For Additional Information:Anna Delgado – Investor Relations(432) 262-2700ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms
Qiagen and Incyte have announced a master collaboration agreement to create a diagnostic panel to aid in the treatment of individuals with a group of rare blood cancers known as myeloproliferative neoplasms (MPNs). This partnership focuses on supporting Incyte's investigational therapies, including the monoclonal antibody INCA033989, which targets mutant calreticulin (mutCALR) in conditions such as myelofibrosis (MF) and essential thrombocythemia (ET). According to the agreement, Qiagen will create a multimodal panel leveraging next-generation sequencing (NGS) to detect clinically relevant gene alterations in haematological malignancies. The validation of the panel will be done by the Illumina NextSeq 550Dx platform as part of Qiagen's collaboration with the latter to provide NGS diagnostic platforms for global laboratory testing. Regulatory submissions and market access activities will be supported by Qiagen across the European Union, the US, and the Asia-Pacific regions. According to Qiagen, MPNs account for approximately 40% of haematological malignancies and are marked by the overproduction of various mature blood cells. Incyte research and development head and president Pablo Cagnoni said: 'Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with Qiagen, which will facilitate CALR testing for patients with MPNs on a global basis. 'The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF.' Incyte's INCA033989 for mutCALR ET or MF aims to eliminate malignant cells while sparing healthy ones. CALR is said to play a crucial role in managing calcium levels within cells and ensuring the production of proteins. Last month, Qiagen entered a commercial collaboration and joint marketing agreement with ID Solutions to expand the availability of digital polymerase chain reaction (dPCR) assays for applications in oncology research. "Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Business Insider
8 hours ago
- Business Insider
Qiagen, Incyte announce collaboration to develop companion diagnostics
QIAGEN (QGEN) and Incyte (INCY) announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms, a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin, which is being developed in myelofibrosis and essential thrombocythemia. Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions.
